- BUSINESS EXPANSION – Commended
- RESEARCH AND DEVELOPMENT – Commended
Clinical Trials Excellence Rankings 2022 – The Verdict
The company has also invested in the development of cardiovascular treatments
One of the key areas where the company has been conducting research is oncology. BMS’ Opdivo drug for muscle-invasive urothelial carcinoma has seen positive results in its Phase II/III trials. In combination with relatlimab the drug has shown a favourable safety and efficacy profile in a melanoma trial. Opdivo has also performed well in combination with Yervoy in a Phase III mesothelioma trial. Opdivo combos have proved their efficiency against lung cancer.
The company has also invested in the development of cardiovascular treatments. Notably, its mavacamten drug has had a positive effect on cardiomyopathy patients according to a Phase III study. Milvexian, co-developed by BMS and Janssen has decreased the risk of postoperative venous thromboembolism (VTE) in a Phase II clinical trial.
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.
The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.